PROGENICS PHARMACEUTICALS IN's ticker is PGNX and the CUSIP is 743187106. A total of 144 filers reported holding PROGENICS PHARMACEUTICALS IN in Q2 2019. The put-call ratio across all filers is 0.54 and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2020 | $227,000 | -28.8% | 59,749 | -4.7% | 0.00% | 0.0% |
Q4 2019 | $319,000 | -2.1% | 62,724 | -2.6% | 0.00% | 0.0% |
Q3 2019 | $326,000 | -17.0% | 64,402 | +1.1% | 0.00% | -50.0% |
Q2 2019 | $393,000 | +32.8% | 63,729 | -0.0% | 0.00% | +100.0% |
Q1 2019 | $296,000 | +7.6% | 63,759 | -2.6% | 0.00% | 0.0% |
Q4 2018 | $275,000 | -33.7% | 65,493 | -1.0% | 0.00% | 0.0% |
Q3 2018 | $415,000 | -9.6% | 66,184 | +15.9% | 0.00% | -50.0% |
Q2 2018 | $459,000 | +36.2% | 57,090 | +26.3% | 0.00% | +100.0% |
Q1 2018 | $337,000 | +0.9% | 45,219 | -19.5% | 0.00% | 0.0% |
Q4 2017 | $334,000 | -18.9% | 56,183 | +0.4% | 0.00% | 0.0% |
Q3 2017 | $412,000 | +14.8% | 55,958 | +5.8% | 0.00% | 0.0% |
Q2 2017 | $359,000 | -11.4% | 52,904 | +23.4% | 0.00% | 0.0% |
Q1 2017 | $405,000 | +17.1% | 42,864 | +7.1% | 0.00% | 0.0% |
Q4 2016 | $346,000 | -99.9% | 40,029 | -0.3% | 0.00% | 0.0% |
Q3 2016 | $254,042,000 | +50.2% | 40,133 | +0.2% | 0.00% | 0.0% |
Q2 2016 | $169,104,000 | -5.0% | 40,072 | -1.8% | 0.00% | 0.0% |
Q1 2016 | $178,000,000 | -72.5% | 40,790 | -61.4% | 0.00% | -66.7% |
Q4 2015 | $647,000,000 | +116266.9% | 105,586 | +8.7% | 0.00% | +50.0% |
Q3 2015 | $556,000 | -99.9% | 97,138 | -23.4% | 0.00% | -50.0% |
Q2 2015 | $945,421,000 | +20.9% | 126,732 | -3.1% | 0.00% | +33.3% |
Q1 2015 | $782,016,000 | -40.5% | 130,772 | -24.8% | 0.00% | -50.0% |
Q4 2014 | $1,315,168,000 | +43.5% | 173,964 | -1.5% | 0.01% | +50.0% |
Q3 2014 | $916,679,000 | +22.1% | 176,624 | +1.4% | 0.00% | +33.3% |
Q2 2014 | $750,625,000 | +17.5% | 174,159 | +11.5% | 0.00% | 0.0% |
Q1 2014 | $639,087,000 | +203.5% | 156,256 | +295.5% | 0.00% | +200.0% |
Q4 2013 | $210,604,000 | +22.4% | 39,513 | +15.5% | 0.00% | 0.0% |
Q3 2013 | $172,086,000 | +22.7% | 34,212 | +8.8% | 0.00% | 0.0% |
Q2 2013 | $140,258,000 | – | 31,448 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Broadfin Capital, LLC | 17,902,338 | $135,342,000 | 5.88% |
TIGER MANAGEMENT L.L.C. | 1,288,454 | $9,741,000 | 1.91% |
Phocas Financial Corp. | 1,047,181 | $7,917,000 | 0.69% |
TUDOR INVESTMENT CORP ET AL | 2,370,503 | $17,921,000 | 0.62% |
EAM Investors, LLC | 553,309 | $4,183,000 | 0.58% |
Baker Brothers Advisors | 4,449,797 | $33,640,000 | 0.34% |
TFS CAPITAL LLC | 463,740 | $3,506,000 | 0.33% |
FEDERATED HERMES, INC. | 13,508,290 | $102,123,000 | 0.32% |
Rotella Capital Management, Inc. | 36,473 | $276,000 | 0.24% |
OXFORD ASSET MANAGEMENT LLP | 1,103,848 | $8,351,000 | 0.18% |